Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Gastric Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Gastroesophageal Junction Adenocarcinoma (160
)
Gastroesophageal Cancer (38
)
Gastric Adenocarcinoma (35
)
Gastroesophageal Junction Adenocarcinoma (160
)
Gastroesophageal Cancer (38
)
Gastric Adenocarcinoma (35
)
›
Associations
(662)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 2 weeks (New A1)
pembrolizumab
Sensitive
:
A1
Pharmabiz - 2wk
pembrolizumab
Sensitive: A1 - Approval
Pharmabiz - 2 weeks
pembrolizumab
Sensitive
:
A1
Pharmabiz - 2 weeks - (New A1)
PD-L1 expression
Gastric Cancer
PD-L1 expression
Gastric Cancer
tislelizumab
Sensitive: B - Late Trials
ASCO-GI 2023 - 3 weeks (New B)
tislelizumab
Sensitive
:
B
ASCO-GI 2023 - 3wk
tislelizumab
Sensitive: B - Late Trials
ASCO-GI 2023 - 3 weeks
tislelizumab
Sensitive
:
B
ASCO-GI 2023 - 3 weeks - (New B)
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
tislelizumab
Sensitive: B - Late Trials
ASCO-GI 2023 - 3 weeks (New B)
tislelizumab
Sensitive
:
B
ASCO-GI 2023 - 3wk
tislelizumab
Sensitive: B - Late Trials
ASCO-GI 2023 - 3 weeks
tislelizumab
Sensitive
:
B
ASCO-GI 2023 - 3 weeks - (New B)
CLDN18.2 positive + HER-2 negative
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive + HER-2 negative
Gastroesophageal Junction Adenocarcinoma
IMAB362
Sensitive: B - Late Trials
ASCO-GI 2023 - 3 weeks (New B)
IMAB362
Sensitive
:
B
ASCO-GI 2023 - 3wk
IMAB362
Sensitive: B - Late Trials
ASCO-GI 2023 - 3 weeks
IMAB362
Sensitive
:
B
ASCO-GI 2023 - 3 weeks - (New B)
CLDN18.2 positive + HER-2 negative
Gastric Cancer
CLDN18.2 positive + HER-2 negative
Gastric Cancer
IMAB362
Sensitive: B - Late Trials
ASCO-GI 2023 - 3 weeks (New B)
IMAB362
Sensitive
:
B
ASCO-GI 2023 - 3wk
IMAB362
Sensitive: B - Late Trials
ASCO-GI 2023 - 3 weeks
IMAB362
Sensitive
:
B
ASCO-GI 2023 - 3 weeks - (New B)
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 negative + PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 3 weeks (New C3)
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 3wk
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 3 weeks
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 negative + PD-L1 expression
Gastric Cancer
HER-2 negative + PD-L1 expression
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 3 weeks (New C3)
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 3wk
nivolumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 3 weeks
nivolumab
Sensitive
:
A1
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
pyrotinib + dalpiciclib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks (New C3)
pyrotinib + dalpiciclib
Sensitive
:
C2
ASCO-GI 2023 - 3wk
pyrotinib + dalpiciclib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks
pyrotinib + dalpiciclib
Sensitive
:
C2
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
camrelizumab + rivoceranib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks (New C3)
camrelizumab + rivoceranib
Sensitive
:
C2
ASCO-GI 2023 - 3wk
camrelizumab + rivoceranib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks
camrelizumab + rivoceranib
Sensitive
:
C2
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 negative
Gastric Cancer
HER-2 negative
Gastric Cancer
camrelizumab + rivoceranib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks (New C3)
camrelizumab + rivoceranib
Sensitive
:
C2
ASCO-GI 2023 - 3wk
camrelizumab + rivoceranib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks
camrelizumab + rivoceranib
Sensitive
:
C2
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
Her-VAXX
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks (New C3)
Her-VAXX
Sensitive
:
C2
ASCO-GI 2023 - 3wk
Her-VAXX
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks
Her-VAXX
Sensitive
:
C2
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
Her-VAXX
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks (New C3)
Her-VAXX
Sensitive
:
C2
ASCO-GI 2023 - 3wk
Her-VAXX
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks
Her-VAXX
Sensitive
:
C2
ASCO-GI 2023 - 3 weeks - (New C3)
MSI-H/dMMR
Gastric Cancer
MSI-H/dMMR
Gastric Cancer
durvalumab + tremelimumab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks (New C3)
durvalumab + tremelimumab
Sensitive
:
C2
ASCO-GI 2023 - 3wk
durvalumab + tremelimumab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks
durvalumab + tremelimumab
Sensitive
:
C2
ASCO-GI 2023 - 3 weeks - (New C3)
CLDN18.2 positive
Gastric Cancer
CLDN18.2 positive
Gastric Cancer
AB011
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks (New C3)
AB011
Sensitive
:
C2
ASCO-GI 2023 - 3wk
AB011
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks
AB011
Sensitive
:
C2
ASCO-GI 2023 - 3 weeks - (New C3)
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CMG901
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks (New C3)
CMG901
Sensitive
:
C2
ASCO-GI 2023 - 3wk
CMG901
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks
CMG901
Sensitive
:
C2
ASCO-GI 2023 - 3 weeks - (New C3)
CLDN18.2 positive
Gastric Cancer
CLDN18.2 positive
Gastric Cancer
CMG901
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks (New C3)
CMG901
Sensitive
:
C2
ASCO-GI 2023 - 3wk
CMG901
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 3 weeks
CMG901
Sensitive
:
C2
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 expression
Gastroesophageal Cancer
HER-2 expression
Gastroesophageal Cancer
ZW25
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
ZW25
Sensitive
:
C3
ASCO-GI 2023 - 3wk
ZW25
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
ZW25
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
durvalumab + tremelimumab
Sensitive
:
C3
ASCO-GI 2023 - 3wk
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
durvalumab + tremelimumab
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
CLDN18.2 positive
Gastroesophageal Junction Adenocarcinoma
AB011
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
AB011
Sensitive
:
C3
ASCO-GI 2023 - 3wk
AB011
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
AB011
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
TMB-H
Gastric Cancer
TMB-H
Gastric Cancer
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
durvalumab + tremelimumab
Sensitive
:
C3
ASCO-GI 2023 - 3wk
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
durvalumab + tremelimumab
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 3wk
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 3wk
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
anlotinib + APL-502
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
anlotinib + APL-502
Sensitive
:
C3
ASCO-GI 2023 - 3wk
anlotinib + APL-502
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
anlotinib + APL-502
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 negative
Gastric Cancer
HER-2 negative
Gastric Cancer
anlotinib + APL-502
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
anlotinib + APL-502
Sensitive
:
C3
ASCO-GI 2023 - 3wk
anlotinib + APL-502
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
anlotinib + APL-502
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
olaparib + durvalumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
olaparib + durvalumab
Sensitive
:
C3
ASCO-GI 2023 - 3wk
olaparib + durvalumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
olaparib + durvalumab
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
PD-L1 expression
Gastric Cancer
PD-L1 expression
Gastric Cancer
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 3wk
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 3wk
paclitaxel + minnelide
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
paclitaxel + minnelide
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
CAPRIN-1 expression
Gastroesophageal Junction Adenocarcinoma
CAPRIN-1 expression
Gastroesophageal Junction Adenocarcinoma
ramucirumab + TRK-950
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
ramucirumab + TRK-950
Sensitive
:
C3
ASCO-GI 2023 - 3wk
ramucirumab + TRK-950
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
ramucirumab + TRK-950
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
CAPRIN-1 expression
Gastric Cancer
CAPRIN-1 expression
Gastric Cancer
ramucirumab + TRK-950
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
ramucirumab + TRK-950
Sensitive
:
C3
ASCO-GI 2023 - 3wk
ramucirumab + TRK-950
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
ramucirumab + TRK-950
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Gastric Cancer
No biomarker
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
No biomarker
Gastric Adenocarcinoma
No biomarker
Gastric Adenocarcinoma
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
No biomarker
Gastric Cancer
No biomarker
Gastric Cancer
TPF
Sensitive: A1 - Approval
TPF
Sensitive
:
A1
TPF
Sensitive: A1 - Approval
TPF
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
TPF
Sensitive: A1 - Approval
TPF
Sensitive
:
A1
TPF
Sensitive: A1 - Approval
TPF
Sensitive
:
A1
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
trastuzumab-pkrb
Sensitive: A1 - Approval
trastuzumab-pkrb
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
trifluridine/tipiracil
Sensitive: A1 - Approval
trifluridine / tipiracil
Sensitive
:
A1
trifluridine/tipiracil
Sensitive: A1 - Approval
trifluridine / tipiracil
Sensitive
:
A1
No biomarker
Gastric Cancer
No biomarker
Gastric Cancer
trifluridine/tipiracil
Sensitive: A1 - Approval
trifluridine / tipiracil
Sensitive
:
A1
trifluridine/tipiracil
Sensitive: A1 - Approval
trifluridine / tipiracil
Sensitive
:
A1
No biomarker
Gastric Cancer
No biomarker
Gastric Cancer
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
No biomarker
Gastric Cancer
No biomarker
Gastric Cancer
capecitabine
Sensitive: A1 - Approval
capecitabine
Sensitive
:
A1
capecitabine
Sensitive: A1 - Approval
capecitabine
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
HER-2 overexpression
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
Zercepac (trastuzumab biosimilar)
Sensitive
:
A1
MSI-H/dMMR
Gastric Cancer
MSI-H/dMMR
Gastric Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login